Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Xiaojian
NCT04652297: Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers	Not yet recruiting	1	76	RoW	HS-10356, Placebo	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Healthy	08/21	08/21
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy	Not yet recruiting	1	24	RoW	Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy	Jiangsu Simcere Pharmaceutical Co., Ltd.	Advanced or Metastatic NSCLC	12/21	10/22
NCT04923607: Phase I Clinical Trial of TQC2731 Injection	Not yet recruiting	1	96	RoW	TQC2731, Placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Asthma Severe Persistent Controlled	08/23	08/23
lan, mu
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy	Not yet recruiting	1	24	RoW	Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy	Jiangsu Simcere Pharmaceutical Co., Ltd.	Advanced or Metastatic NSCLC	12/21	10/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Xiaojian
NCT04652297: Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers	Not yet recruiting	1	76	RoW	HS-10356, Placebo	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Healthy	08/21	08/21
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy	Not yet recruiting	1	24	RoW	Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy	Jiangsu Simcere Pharmaceutical Co., Ltd.	Advanced or Metastatic NSCLC	12/21	10/22
NCT04923607: Phase I Clinical Trial of TQC2731 Injection	Not yet recruiting	1	96	RoW	TQC2731, Placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Asthma Severe Persistent Controlled	08/23	08/23
lan, mu
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy	Not yet recruiting	1	24	RoW	Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy	Jiangsu Simcere Pharmaceutical Co., Ltd.	Advanced or Metastatic NSCLC	12/21	10/22